Everything below concerns MC4R. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-02-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
Bremelanotide is a synthetic cyclic heptapeptide that acts on a family of G-protein-coupled receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide associated with pigmentation and several central signalling pathways. A lactam bridge constrains the ring and slows enzymatic breakdown, which distinguishes it from the linear parent molecule. Research interest moved over time from pigment biology toward central nervous system effects, particularly circuits connected to sexual desire. Parenteral delivery is used because oral bioavailability is poor.
Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.
Published discussion sits at the intersection of peptide chemistry, neuroendocrinology and sexual medicine. Trial reports emphasise change scores on validated instruments, while mechanistic papers focus on hypothalamic circuits and receptor selectivity. Because placebo response in this field is large, effect sizes are usually reported with confidence intervals rather than as isolated averages. Reviews note that female and male data sets are not interchangeable and should be read separately. Diagnostic terminology has been revised over time, which complicates comparison between older and newer studies.
The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-MSH |
| Molecular mass | Approximately 1025 Da | Peptide-scale molecule |
| Route | Subcutaneous injection | Intranasal form used in early research |
| Common synonyms | PT-141; bremelanotide acetate | Research code and salt form |
| Typical storage | 2-8 °C, protected from light | Unopened vial condition |
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
The North American Aviation P-51 Mustang is an American long-range, single-seat fighter and fighter-bomber used during World War II and the Korean War, among other conflicts. The Mustang was designed in 1940 by a team headed by James H. Kindelberger of North American Aviation (NAA) in response to a request from the British Purchasing Commission. The commission approached NAA to build Curtiss P-40 fighters under license for the Royal Air Force (RAF). Rather than build an old design from another company, NAA proposed the design and production of a more modern fighter. The prototype NA-73X airframe was completed on 9 September 1940, 102 days after contract signing, achieving its first flight on 26 October. The Mustang was designed to use the Allison V-1710 engine without an export-sensitive turbocharger or a multi-stage supercharger, resulting in limited high-altitude performance. The aircraft was first flown operationally by the RAF as a tactical-reconnaissance aircraft and fighter-bomber (Mustang Mk I). In mid 1942, a development project known as the Rolls-Royce Mustang X, replaced the Allison engine with a Rolls-Royce Merlin 65 two-stage inter-cooled supercharged engine. During testing at Rolls-Royce's airfield at Hucknall in England, it was clear the engine dramatically improved the aircraft's performance at altitudes above 15,000 ft (4,600 m) without sacrificing range.
Professional divers are screened for risk factors during initial and periodical medical examination for fitness to dive. In most cases recreational divers are not medically screened, but are required to provide a medical statement before acceptance for training in which the most common and easy to identify risk factors must be declared. If these factors are declared, the diver may be required to be examined by a medical practitioner, and may be disqualified from diving if the conditions indicate. Asthma, Marfan syndrome, and COPD pose a very high risk of pneumothorax. In some countries these may be considered absolute contraindications, while in others the severity may be taken into consideration. Asthmatics with a mild and well controlled condition may be permitted to dive under restricted circumstances.
=== Centipawn: Chess position === Chess software frequently uses centipawns internally or externally as a unit measuring how strong each player's situation position is, and hence also by how much one player is beating the other, and how strong a possible move is. 100 centipawns = the value of 1 pawn – more specifically, something like the average value of the pawns at the start of the game, as the actual value of pawns depends on their position. Loss of a pawn will therefore typically lose that player 100 centipawns. The centipawn is often used for comparing possible moves, as in a given position, chess software will often rate the better of two moves within a few centipawns of each other.
Sources: en.wikipedia.org
Some ant species are considered as pests, primarily those that occur in human habitations, where their presence is often problematic. For example, the presence of ants would be undesirable in sterile places such as hospitals or kitchens. Some species or genera commonly categorized as pests include the Argentine ant, immigrant pavement ant, yellow crazy ant, banded sugar ant, pharaoh ant, red wood ant, black carpenter ant, odorous house ant, red imported fire ant, and European fire ant. Some ants will raid stored food, some will seek water sources, others may damage indoor structures, some may damage agricultural crops directly or by aiding sucking pests. Some will sting or bite. The adaptive nature of ant colonies make it nearly impossible to eliminate entire colonies and most pest management practices aim to control local populations and tend to be temporary solutions. Ant populations are managed by a combination of approaches that make use of chemical, biological, and physical methods. Chemical methods include the use of insecticidal bait which is gathered by ants as food and brought back to the nest where the poison is inadvertently spread to other colony members through trophallaxis. Management is based on the species and techniques may vary according to the location and circumstance.
It has been shown that injection of peptide amphiphile solutions in vivo leads to in situ gel formation due to the presence of counterions in physiological solutions. This, along with the complete biodegradability of the materials, suggests numerous applications in in vitro and in vivo therapies.
Alphavirus infection Asymmetric periflexural exanthem of childhood (unilateral laterothoracic exanthem) B virus infection Boston exanthem disease Bovine papular stomatitis Bowenoid papulosis Buffalopox Butcher's wart Chikungunya fever Condylomata acuminata Congenital rubella syndrome Cowpox Cytomegalic inclusion disease Dengue (Break-bone fever) Disseminated herpes zoster Eczema herpeticum (Kaposi's varicelliform eruption) Eczema vaccinatum Epidermodysplasia verruciformis Eruptive pseudoangiomatosis Erythema infectiosum (fifth disease, slapped cheek disease) Exanthem of primary HIV infection (acute retroviral syndrome) Farmyard pox Generalized vaccinia Genital herpes (herpes genitalis, herpes progenitalis) Gianotti–Crosti syndrome (infantile papular acrodermatitis, papular acrodermatitis of childhood, papulovesicular acrolocated syndrome) Giant condyloma acuminatum (Buschke–Löwenstein tumor, giant condyloma of Buschke–Löwenstein tumor) Hand-foot-and-mouth disease Heck's disease (focal epithelial hyperplasia) Hemorrhagic fever with renal syndrome Hepatitis B Hepatitis C Herpangina Herpes gladiatorum (scrum pox) Herpes simplex Herpes zoster oticus (Ramsay–Hunt syndrome) Herpetic keratoconjunctivitis Herpetic sycosis Herpetic whitlow HIV-associated pruritus Human monkeypox Human T-lymphotropic virus 1 infection Human tanapox Immune reconstitution inflammatory syndrome (immune recovery syndrome) Infectious mononucleosis (glandular fever) Inflammatory skin lesions following zoster infection (isotopic response) Intrauterine herpes simplex Kaposi sarcoma Lassa fever Lipschütz ulcer (ulcus vulvae acutum) Measles (rubeola, morbilli) Milker's nodule Modified varicella-like syndrome Molluscum contagiosum Myrmecia Neonatal herpes simplex Ophthalmic zoster Orf (contagious pustular dermatosis, ecthyma contagiosum, infectious labial dermatitis, sheep pox) Orf-induced immunobullous disease Orolabial herpes (herpes labialis) Papular purpuric gloves and socks syndrome Pigmented wart Postherpetic neuralgia (zoster-associated pain) Post-vaccination follicular eruption Progressive vaccinia (vaccinia gangrenosum, vaccinia necrosum) Pseudocowpox Recurrent respiratory papillomatosis (laryngeal papillomatosis) Rift Valley fever Roseola infantum (exanthem subitum, exanthema subitum, sixth disease) Roseola vaccinia Rubella (German measles) Sandfly fever (Pappataci fever, phlebotomus fever) Sealpox Varicella (chickenpox) Variola major (smallpox) Verruca plana (flat wart) Verruca plantaris (plantar wart) Verruca vulgaris (wart) Verrucae palmares et plantares Viral-associated trichodysplasia (ciclosporin-induced folliculodystrophy) Wasting syndrome West Nile virus infection Zoster (herpes zoster, shingles) Zoster sine herpete
Sources: en.wikipedia.org
== Principle == Delayed neutrons are associated with the beta decay of the fission products. After prompt fission neutron emission the residual fragments are still neutron rich and undergo a beta decay chain. The more neutron rich the fragment, the more energetic and faster the beta decay. In some cases the available energy in the beta decay is high enough to leave the residual nucleus in such a highly excited state that neutron emission instead of gamma emission occurs. Using U-235 as an example, this nucleus absorbs thermal neutrons, and the immediate mass products of a fission event are two large fission fragments, which are remnants of the formed U-236 nucleus. These fragments emit two to three free neutrons (2.43 on average), called "prompt" neutrons. A subsequent fission fragment occasionally undergoes a stage of radioactive decay (which is a beta minus decay) that yields a new nucleus (the emitter nucleus) in an excited state that emits an additional neutron, called a "delayed" neutron, to get to ground state. These neutron-emitting fission fragments are called delayed neutron precursor atoms. The longest-lived groups can be traced to specific decay chains. In about 70% of 87Br beta decays (half-life 55 s), the 87Kr daughter is left in a nuclear state above the 5.4 MeV needed to eject its last neutron; it promptly releases a neutron, ending as stable 86Kr. The neutron emission rate is set by the rate of formation of 87Kr, so the group carries the 55 s half-life of the precursor.
Snakes (especially Elapidae and Viperidae) are the leading cause of envenomings and antivenoms are in constant short supply in high risk areas due to the strenuous productive methods (Immunised animals) and the strict storage preferences (Constant below 0OC storage). This problem continues, when the medicine itself has limited effects on localised tissue and inevitably causes either acute (anaphylactic or pyrogenic) and delayed (serum sickness type) reactions in most patients. However, by using different ‘omic’ technologies, the use of ‘Antivenomics’ can potentially make safer, more cost effective and less time-consuming ways of producing antivenoms for a range of toxic organisms. New antivenom methods are even being investigated today with the use of monoclonal antibodies (mAbs) and the expansion of venomous databases, allowing for more effective approaches when screening of cross-reactivity of antivenoms. Lastly, agriculture can be improved upon by enhanced-venomic techniques through the invention of insect-specific biopesticides created from venom. Insects are both an agricultural/horticultural pest and act as vector/carriers of many parasites and disease. Ergo, effective insecticides are always needed to control the destructive effects of many insect species. However, many insecticides used in the past, do not meet current regulations and have been banned due to harmful effects such as affecting non-target species (DDT) and having a high toxicity level towards mammals (Neonicotinoids).
Following the 1984 tour, Fripp dissolved King Crimson for the second time, exactly ten years after the band's 1974 split. Bruford and Belew expressed frustration over this; Belew recalled the first he had heard of it was through a report in Musician magazine.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide that activates melanocortin receptors. It is given by injection and was approved in the United States in 2019 for a specific low-desire diagnosis in premenopausal women. It is not a hormonal therapy.
Earlier approaches were largely hormonal or psychological in focus, whereas this compound acts on central melanocortin signalling. It is not a vasodilator and does not share the mechanism of phosphodiesterase inhibitors. Head-to-head comparative data are limited.
Placebo responses in desire trials are large, so the average drug-placebo separation is small. Reporting therefore relies on validated questionnaires with statistical ranges. Individual responses vary widely.
Reported activity is highest at MC4R, with lower potency at MC1R and MC3R. The MC4R interaction is generally treated as the most relevant to its central effects. Selectivity is not absolute, and activity across the family is dose-dependent.